Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
172 hedge funds and large institutions have $4.11B invested in Intercept Pharmaceuticals, Inc. in 2014 Q1 according to their latest regulatory filings, with 99 funds opening new positions, 27 increasing their positions, 43 reducing their positions, and 15 closing their positions.
560% more first-time investments, than exits
New positions opened: 99 | Existing positions closed: 15
392% more capital invested
Capital invested by funds: $835M → $4.11B (+$3.27B)
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
95% more funds holding
Funds holding: 88 → 172 (+84)
92% more call options, than puts
Call options by funds: $100M | Put options by funds: $52.2M
37% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$384M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$339M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$192M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$154M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$107M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$420M |
| 2 |
VAM
Visium Asset Management
New York
|
-$225M |
| 3 |
Millennium Management
New York
|
-$101M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$72.5M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$72.3M |
ICPT Hedge Fund Activity: Q1 2014 in Review
172 of the 3,463 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2014, worth a combined $4.11B — up 392% from $835M a quarter earlier.
Buyers outnumbered sellers: 99 funds opened new ICPT positions and 15 closed out — a net gain of 84 holders — while 27 added to existing stakes and 43 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $384M. The largest seller was SAC Capital Advisors, cutting an estimated $420M.
- 172 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2014, up from 88 in Q4 2013.
- Funds reported $4.11B of Intercept Pharmaceuticals, Inc. stock for Q1 2014, up 392% quarter-over-quarter.
- 99 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2014 and 15 closed out, a net change of +84 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2014 was Jennison Associates, an estimated $384M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q1 2014 was SAC Capital Advisors, an estimated $420M sold.
Based on aggregated 13F filings for Q1 2014.